

JUNE 15, 2006

To: All Pharmacy Providers and Prescribing Practitioners

Subject: Changes to the Preferred Drug List

Note: The information referenced in this bulletin is not directed to those providers rendering services in the risk-based managed care (RBMC) delivery system.

Overview

This bulletin announces the Preferred Drug List (PDL) decisions made at the May 26, 2006 Drug Utilization Review (DUR) Board meeting. These decisions are based on the recommendations from the Therapeutics Committee meeting held on May 5, 2006. Refer to Table 1 for a summary of these changes.

These changes are effective July 1, 2006.

Table 1 - Approved Changes to the PDL, Effective July 1, 2006

Drug Class	Drug	PDL Status
Brand-Name Narcotics	Anexsia	Non-PDL
Brand-Name Narcotics	Ultram ER	Non-PDL (quantity limit of one tablet per day)
Triptans	Imitrex STATdose 4 mg	PDL (quantity limit of 1 box of 2 injections per month on syringe and refill packages)
Anti-Diabetic Agents	Glimepiride	PDL
Anti-Diabetic Agents	Glipizide/Metformin	PDL (step-edit – must fail one of the agents in combo)
Anti-Diabetic Agents	Glyburide/Metformin	PDL (step-edit – must fail one of the agents in combo)
Anti-Diabetic Agents	Avandaryl	PDL (step-edit – must fail one of the agents in combo)
Anti-Diabetic Agents	Amaryl	Non-PDL
Anti-Diabetic Agents	Metaglip	Non-PDL (step-edit – must fail one of the agents in combo)
Bone Resorption Suppression Agents	Etidronate	PDL

(Continued)

Table 1 - Approved Changes to the PDL, Effective July 1, 2006

Drug Class	Drug	PDL Status
Bone Resorption Suppression Agents	Boniva 3 mg/3 ml Single-Use, Pre-filled Syringe	Non-PDL (quantity limit of one single-use, pre-filled syringe per 90 days)

OTC Drug Formulary Addition

The DUR Board approved the addition of Magonate to the Over the Counter (OTC) Drug Formulary effective July 1, 2006. Providers will be notified of the rate as soon as it is available.

Information Access

Providers can access the PDL at http://www.indianapbm.com. Notice of the DUR Board meetings and agendas are posted on the Family and Social Services Administration (FSSA) Web site at http://www.state.in.us/fssa/ under the tab titled Calendar. Information about the Therapeutics Committee and the PDL is available at http://www.indianapbm.com.

Contact Information

Direct prior authorization (PA) requests and questions regarding the PDL to the ACS Clinical Call Center at 1-866-879-0106. Direct questions about this bulletin to EDS Customer Assistance at (317) 655-3240 in the Indianapolis local area, or 1-800-577-1278.